Insider Surge: Ideaya Biosciences Executives Buy Shares as CEO Signals 2026 Breakthroughs—Stocks Stay Steady Amid Volatile Market
Insider buying shows Ideaya’s leaders stay bullish on oncology trials—high‑risk, high‑reward, but a potentially attractive entry point for growth‑focused investors.
2 minutes to read